Organon & Co. Common Stock vs Seagate Technology Holdings PLC — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Seagate Technology Holdings PLC trades at $684.65 (market cap $169.91B). The key difference: Seagate Technology Holdings PLC is far larger — about 46.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Seagate Technology Holdings PLC for 41 Days on average.
| OGN | STX | |
|---|---|---|
Market Cap | $3.62B | $169.91B |
Volume | 2,892,999 | 6,791,866 |
Sector | Health | Technology |
52-Week High | $13.81 | $1.09K |
52-Week Low | $5.70 | $214.40 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $11.04B | $172.06B |
Dividend Yield | 0.58% | 0.4% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Seagate Technology (STX) trades at $713.54, down 5.27% amid concerns over increased competition from Toshiba's AI storage expansion plans. The stock shows strong profitability with a 26.11% net margin and has beaten EPS estimates for three consecutive quarters. Technical indicators are bearish, with the price below key support levels, while analyst consensus remains positive with a $1,130 price target.
Outlook: Long-term growth is supported by AI-driven storage demand and robust earnings, but near-term risks include competitive pressures and high valuation multiples. The stock presents a contrarian opportunity if competitive fears ease, though volatility may persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →